Sofie Wilgenhof
- Immunology top 2%
- Immunotherapy and Immune Responses 36
- Oncology top 1%
- Cancer Immunotherapy and Biomarkers 39
- CAR-T cell therapy research 37
- Cutaneous Melanoma Detection and Management 15
- Molecular Biology top 10%
- Melanoma and MAPK Pathways 22
- RNA Interference and Gene Delivery 9
- vaccines and immunoinformatics approaches 7
- Cancer Research top 10%
-
- Renal cell carcinoma treatment 7
- Co-authors
- Bart NeynsKris ThielemansJurgen CorthalsJohn B.A.G. HaanenCarlo HeirmanMaartje W. RohaanAude BonehillAn M. T. Van Nuffel
- Cited by
- ImmunologyOncologyMolecular Biology
- Journals
- Journal of Clinical Oncology (15 papers)Annals of Oncology (13 papers)Melanoma Research (8 papers)
- Partner nations
- BelgiumNetherlandsUnited States
In The Last Decade
Sofie Wilgenhof
82 papers receiving 2.6k citations
Hit Papers
Peers
Comparison fields: 5 of 100
- Immunology 1.4k
- Oncology 1.8k
- Molecular Biology 1.1k
- Cancer Research 211
- Pulmonary and Respiratory Medicine 391
Countries citing papers authored by Sofie Wilgenhof
This map shows the geographic impact of Sofie Wilgenhof's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sofie Wilgenhof with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sofie Wilgenhof more than expected).
Fields of papers citing papers by Sofie Wilgenhof
This network shows the impact of papers produced by Sofie Wilgenhof. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sofie Wilgenhof. The network helps show where Sofie Wilgenhof may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Sofie Wilgenhof, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2024 | 8 | |
| 3 | 2024 | 4 | |
| 4 | 2023 | 1 | |
| 5 | 2023 | 4 | |
| 6 | 2023 | 1 | |
| 7 | 2022 | 1 | |
| 8 | Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumorsbreakdown → | 2021 | 257 |
| 9 | 2020 | 1 | |
| 10 | 2019 | 9 | |
| 11 | 2018 | 7 | |
| 12 | 2017 | 21 | |
| 13 | 2016 | 240 | |
| 14 | 2016 | 24 | |
| 15 | 2016 | 116 | |
| 16 | 2015 | 33 | |
| 17 | 2014 | 33 | |
| 18 | 2013 | 170 | |
| 19 | 2012 | 42 | |
| 20 | 2012 | 8 |
About Sofie Wilgenhof
Sofie Wilgenhof is a scholar working on Oncology, Immunology, Molecular Biology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 86 papers that have together received 2.7k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (39 papers), CAR-T cell therapy research (37 papers), Immunotherapy and Immune Responses (36 papers), Melanoma and MAPK Pathways (22 papers), Cutaneous Melanoma Detection and Management (15 papers), RNA Interference and Gene Delivery (9 papers), Renal cell carcinoma treatment (7 papers) and vaccines and immunoinformatics approaches (7 papers). The work is most often cited by research in Immunology (1.4k citations), Oncology (1.8k citations), Molecular Biology (1.1k citations), Cancer Research (211 citations) and Pulmonary and Respiratory Medicine (391 citations). Sofie Wilgenhof has collaborated with scholars based in Belgium, Netherlands and United States. Frequent co-authors include Bart Neyns, Kris Thielemans, Jurgen Corthals, John B.A.G. Haanen, Carlo Heirman, Maartje W. Rohaan, Aude Bonehill, An M. T. Van Nuffel, Daphné Benteyn and Nicolas van Baren. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Melanoma Research, Cancer Immunology Immunotherapy and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.